المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: ISSN: 2589-5559.

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest

المؤلفون: Villeret, François, Dharancy, Sébastien, Erard, Domitille, Abergel, Armand, Barbier, Louise, Besch, Camille, Boillot, Olivier, Boudjema, Karim, Coilly, Audrey, Conti, Filomena, Corpechot, Christophe, Duvoux, Christophe, Faitot, François, Faure, Stéphanie, Francoz, Claire, Giostra, Emiliano, Gugenheim, Jean, Hardwigsen, Jean, Hilleret, Marie-Noëlle, Hiriart, Jean-Baptiste, Houssel-Debry, Pauline, Kamar, Nassim, Lassailly, Guillaume, Latournerie, Marianne, Pageaux, Georges-Philippe, Samuel, Didier, Vanlemmens, Claire, Saliba, Faouzi, Dumortier, Jérôme

المساهمون: Hospices Civils de Lyon (HCL), Institute for Translational Research in Inflammation - U 1286 (INFINITE (Ex-Liric)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Physiopathologie et traitement des maladies du foie, Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique EHESP (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

المصدر: EISSN: 2589-5559 ; JHEP Reports Innovation in Hepatology ; https://univ-rennes.hal.science/hal-04020048Test ; JHEP Reports Innovation in Hepatology, 2023, 5 (3), pp.100668. ⟨10.1016/j.jhepr.2022.100668⟩

مصطلحات موضوعية: MS, metabolic syndrome, NAFLD recurrence, NAFLD, non-alcoholic fatty liver disease, NASH, non-alcoholic steatohepatitis, mTOR-i, mTOR inhibitor, ABM, Agence de la Biomédecine, BS, bariatric surgery, CNI, calcineurin inhibitor, CST, corticosteroid, CV, cardiovascular, CYA, cyclosporine, ESLD, end-stage liver disease, HCC, hepatocellular carcinoma, LT, liver transplantation, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology

الوصف: International audience ; Background & aims: Liver transplantation (LT) is the only available treatment for end-stage non-alcoholic fatty liver disease (NAFLD) (related decompensated cirrhosis and/or hepatocellular carcinoma). The aim of our study was to evaluate the risk of disease recurrence after LT and the factors influencing it.Method: This retrospective multicenter study included adults transplanted for NAFLD cirrhosis between 2000 and 2019 in 20 participating French-speaking centers. Disease recurrence (steatosis, steatohepatitis and fibrosis) was diagnosed from liver graft biopsies.Results: We analyzed 150 patients with at least one graft liver biopsy available ≥6 months after transplantation, among 361 patients transplanted for NAFLD. The median (IQR) age at LT was 61.3 (54.4-64.6) years. The median follow-up after LT was 4.7 (2.8-8.1) years. The cumulative recurrence rates of steatosis and steatohepatitis at 5 years were 80.0% and 60.3%, respectively. Significant risk factors for steatohepatitis recurrence in multivariate analysis were recipient age at LT <65 years (odds ratio [OR] 4.214; p = 0.044), high-density lipoprotein-cholesterol <1.15 mmol/L after LT (OR 3.463; p = 0.013) and grade ≥2 steatosis on the graft at 1 year after LT (OR 10.196; p = 0.001). The cumulative incidence of advanced fibrosis (F3-F4) was 20.0% at 5 years after LT and significant risk factors from multivariate analysis were metabolic syndrome before LT (OR 8.550; p = 0.038), long-term use of cyclosporine (OR 11.388; p = 0.031) and grade ≥2 steatosis at 1 year after LT (OR 10.720; p = 0.049). No re-LT was performed for NAFLD cirrhosis recurrence.Conclusion: Our results strongly suggest that recurrence of initial disease after LT for NAFLD is inevitable and progressive in a large proportion of patients; the means to prevent it remain to be further evaluated.Impact and implications: Non-alcoholic fatty liver disease (NAFLD) is a growing indication for liver transplantation, but the analysis of disease recurrence, based ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36852108; hal-04020048; https://univ-rennes.hal.science/hal-04020048Test; https://univ-rennes.hal.science/hal-04020048/documentTest; https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest; PUBMED: 36852108; PUBMEDCENTRAL: PMC9957774

الإتاحة: https://doi.org/10.1016/j.jhepr.2022.100668Test
https://univ-rennes.hal.science/hal-04020048Test
https://univ-rennes.hal.science/hal-04020048/documentTest
https://univ-rennes.hal.science/hal-04020048/file/hal-04020048.pdfTest